Established in 1926 in Europe, the Recordati Group is a public global pharmaceutical company committed to the research and development of unique treatments for rare diseases and new medicines mainly for cardiovascular and urogenital disorders.

Recordati Rare Diseases is part of the rare diseases business within the Recordati Group, and is dedicated to developing innovative, high-impact therapies. Our focus is mainly on those who we believe need it most—people affected by rare diseases. They serve as our top priority and sit at the centre of everything we do